NCT07413796 Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures
| NCT ID | NCT07413796 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Warsaw |
| Condition | Brain Tumor Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 382 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 382 participants in total. It began in 2026-02-01 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to compare two commonly used methods of closing the skin after surgery for an intracranial tumor. Skin closure is one of the most important steps in neurosurgical procedures, as it has a major influence on how well the wound heals. In patients with brain tumors, proper wound healing is especially important because it may affect how soon additional treatments, such as radiotherapy or chemotherapy, can be started. There are different ways to close the skin after surgery, including running sutures and interrupted sutures. Both methods are widely used and considered safe. However, in oncological neurosurgery, there is limited scientific evidence comparing their effects, and the choice of technique is often based on the surgeon's personal experience. In this study, investigators will compare skin closure using running absorbable sutures with interrupted non-absorbable sutures. Investigators will evaluate how well, depending on used suturing methods, the wound heals and how often wound-related complications occur, such as infection, separation of the wound edges, or leakage of cerebrospinal fluid. Investigators believe that the results of this study will help improve wound care in patients undergoing neurosurgical treatment for brain tumors and, as a result, may contribute to better recovery and overall quality of life.
Eligibility Criteria
Inclusion Criteria: * Male or female at least 18 years old * Qualified for a craniotomy due to supratentorial intracranial tumor Exclusion Criteria: * Revision surgery due to recurrent brain tumor * Emergency neurosurgical procedure * Scalp incision involving glabrous skin (e.g. forehead) or facial regions (e.g. eyebrow)
Contact & Investigator
Michał Senger, M.D.
PRINCIPAL INVESTIGATOR
Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland
Frequently Asked Questions
Who can join the NCT07413796 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Tumor Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07413796 currently recruiting?
Yes, NCT07413796 is actively recruiting participants. Contact the research team at michal.senger@wum.edu.pl for enrollment information.
Where is the NCT07413796 trial being conducted?
This trial is being conducted at Warsaw, Poland.
Who is sponsoring the NCT07413796 clinical trial?
NCT07413796 is sponsored by Medical University of Warsaw. The principal investigator is Michał Senger, M.D. at Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland. The trial plans to enroll 382 participants.